• No results found

New RNA playgrounds : non-coding RNAs and RNA-binding proteins control cellular processes Kedde, M.

N/A
N/A
Protected

Academic year: 2021

Share "New RNA playgrounds : non-coding RNAs and RNA-binding proteins control cellular processes Kedde, M."

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Citation

Kedde, M. (2009, January 22). New RNA playgrounds : non-coding RNAs and RNA-binding proteins control cellular processes. Retrieved from

https://hdl.handle.net/1887/13414

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/13414

Note: To cite this publication please use the final published version (if applicable).

(2)

New RNA playgrounds

non-coding RNAs and

RNA-binding proteins control cellular processes

Martijn Kedde

(3)
(4)

New RNA playgrounds

non-coding RNAs and regulatory

RNA-binding proteins control cellular processes

proefschrift

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden,

op gezag van Rector Magnificus prof. mr. P.F. van der Heijden, volgens het besluit van het College voor Promoties

te verdedigen op donderdag 22 januari 2009 klokke 13.45 uur

door Martijn Kedde

geboren te Ede in 1979

(5)

Promotor: Prof. Dr. J.J. Neefjes Co-Promotor: Dr. R. Agami

(Nederlands Kanker Instituut, Amsterdam) Referent: Prof. Dr. R.H. Medema

(Universiteit Utrecht)

Overige Leden: Prof. Dr. R. Bernards (Universiteit Utrecht) Dr. R.F. Ketting (Universiteit Utrecht)

Prof. Dr. T.N.M. Schumacher

Prof. Dr. L.H.F. Mullenders Dr. A.G. Jochemsen

© 2008, M. Kedde

Cover: ‘Dagrecreatie: Spelende kinderen in een speeltuin’ 18 augustus 1953, herkomst: stadsarchief Amsterdam.

The research in this thesis was performed at the department of Tumor Biology at the Netherlands Cancer Institute (NKI) and supported by the Dutch Cancer Society (KWF) and a European Young Investigator award (EURYI) to Reuven Agami. The printing of this thesis was supported by the Dutch Cancer Society (KWF).

Printed by: Wöhrmann Print Service, Zutphen

(6)

Contents

Chapter 1: General introduction and outline of this thesis 7

Chapter 2: Interplay between microRNAs and RNA-binding 25 proteins determines developmental processes

Cell Cycle, 2008

Chapter 3: RNA-Binding Protein Dnd1 Inhibits MicroRNA 39 Access to Target mRNA

Cell, 2007

Chapter 4: Telomerase-independent regulation of ATR by 65 human telomerase RNA

Journal of Biological Chemistry, 2006

Chapter 5: miR-148 targets human DNMT3b protein coding 83 region

RNA, 2008

Chapter 6: General discussion 91

Nederlandse samenvatting 101

Curriculum vitae 105

List of publications 107

(7)

Referenties

GERELATEERDE DOCUMENTEN

49 Since inhibition of Dnd1 expression in human testicular germ cell tumor cell lines resulted in the loss of miR-373 family targets, it is possible that a balance

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden Downloaded.

In chapter 4 I have investigated the role of hTR, the RNA component of telomerase (an enzyme involved in the acquired capability of cancer cells to reach a limitless

2 Dnd1 function is essential for proper development of primordial germ cells (PGCs) in zebrafish and mammals, indicating a crucial role for RBP/miRNA interplay on 3’UTRs of mRNAs

Here we demonstrate that the expression of dead end 1 Dnd1, an evolutionary conserved RNAbinding protein RBP, counteracts the function of several miRNAs in human cells and in

RPA performed on extracts from MCF7 cells transfected with CMV-hTR, or CMV-control constructs, cells were harvested 4 days after transfection.. Quantification was performed

To assess whether increasing the miR-148 level would result in a reduced endogenous DNMT3b1 protein level, we electroporated the miR-148 expression vector into 2102EP cells

The research described in this thesis was performed at the Division of Tumor Biology of the Netherlands Cancer Institute (NKI/AvL) and supported by The Netherlands Organization